By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arrowhead Research Corporation 

1118 East Green Street

Pasadena  California  91106  U.S.A.
Phone: 626-792-5549 Fax: 626-792-5554


Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

Key Statistics

Ownership: Public

Web Site: Arrowhead Research Corporation
Symbol: ARWR

Medical Device

Company News
Arrowhead Research Corporation (ARWR) Presents Data Showing Robust Sustained Anti-viral Effects With ARC-520 In Hepatitis B Infected Chimpanzees 11/16/2015 12:01:03 PM
Arrowhead Research Corporation (ARWR) Late-Breaking Clinical Data Shows That ARC-520 Can Produce Deep And Durable Reductions Of Hepatitis B Viral Antigens And DNA 11/16/2015 10:54:19 AM
Arrowhead Research Corporation (ARWR) To Present At Upcoming Conferences 11/11/2015 10:48:11 AM
Arrowhead Research Corporation (ARWR) Late-Breaker Abstract Accepted For Presentation At The American Association for Study of Liver Diseases Liver Meeting 2015 10/20/2015 10:47:45 AM
Arrowhead Research Corporation (ARWR) Presents Overview Of Its Broad RNAi Delivery Platform And Introduces New Subcutaneously Administered Format 10/14/2015 1:08:42 PM
Arrowhead Research Corporation (ARWR) To Present At Upcoming Conferences 10/5/2015 9:50:04 AM
Arrowhead Research Corporation (ARWR) Reports Peak Reduction In HBSAg Of Up To 99% (1.9 Log) After A Single Dose With Hepatitis B Candidate ARC-520 In Treatment Naïve Cohort Of Phase IIa Study 9/24/2015 10:23:55 AM
Arrowhead Research Corporation (ARWR) Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC Delivery System 9/11/2015 10:21:55 AM
Arrowhead Research Corporation (ARWR) To Webcast Analyst Day Presentation On Hepatitis B Candidate ARC-520 9/10/2015 11:12:36 AM
Arrowhead Research Corporation (ARWR) To Present At Jefferies and Co. 2015 Hepatitis B Summit 8/5/2015 11:55:47 AM